Vismodegib and orbital excision for treating locally advanced basal cell carcinoma
Authors Hogarty DT, Dewhurst NG, Burt B
Received 19 March 2018
Accepted for publication 10 May 2018
Published 31 July 2018 Volume 2018:11 Pages 177—179
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Scott Fraser
Daniel T Hogarty,1 Nicholas G Dewhurst,1 Benjamin Burt1–4
1Bendigo Eye Clinic, Bendigo, VIC, Australia; 2Royal Victorian Eye and Ear Hospital, Melbourne, VIC, Australia; 3Cosmetic Surgery for Women, Melbourne, VIC, Australia; 4Canberra Oculoplastics, Barton, Canberra, ACT, Australia
Purpose: Orbital invasion of periocular basal cell carcinoma (BCC) is a potentially life-threatening condition with high levels of ocular morbidity. Exenteration results in significant disfigurement and permanent loss of vision. We report our experience with a patient who presented with medial orbit invasion of a BCC following 2 previous microscopically adequate local excisions of medial canthal BCC, an adequate Moh’s micrographic surgical excision of the tumor, and radiotherapy. The patient underwent an orbital excision where the tumor was found to have perineural involvement and extend beyond the posterior margin. Following the pathology results of this procedure, the patient opted to try vismodegib (Erivedge®) to delay exenteration for as long as possible.
Observations: A course of vismodegib was taken by the patient with minor side effects (partial alopecia, mild dysgeusia and hyposmia, and minor muscle cramps). Subsequent imaging demonstrated no recurrence of the orbital tumor 29 months after orbital excision.
Conclusion and importance: We demonstrate the use of vismodegib with local orbital excision as an eye-saving alternative to exenteration for advanced orbital metastasis of BCC.
Keywords: basal cell carcinoma, hedgehog pathway inhibitor, vismodegib, perineural, locally advanced basal cell carcinoma
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]